Item Details
Chinese Pharma Deal Reaches US$358 Million Upfront
On 6 November, Sino Biopharmaceutical signed a licensing agreement covering six preclinical cancer drugs with Boehringer Ingelheim. The upfront payment is US$358 million, with additional milestone payments possible. HPC can support pharmaceutical sourcing and healthcare-sector partnerships.
Get in Touch
We’ll get back to you shortly.